Shots:

• The collaboration will evaluate Fusion's FPI-1434 + Merck's Keytruda in patients with solid tumors expressing IGF-1R. Fusion will sponsor the study and Merck will supply Keytruda
• The companies plan to initiate a P-I/II trial to evaluate the safety- tolerability- and PK of combination therapy and is expected in ~6 to 9 mos. upon achieving the RP2D in the ongoing P-I study of FPI-1434 monothx
• The preclinical data demonstrated promising activity with FPI-1434 and immuno-oncology agents. The collaboration aims to expand the radiopharmaceutical therapies- including advancing in earlier cancer therapy lines

  Ref: PRNewswire | Image: Merck